FTC Announces Conditions on GSK and Novartis Joint Venture Agreement
The US Federal Trade Commission will require Novartis AG to divest its nicotine replacement therapy patch business to continue the joint venture with GlaxoSmithKline.
The Federal Trade Commission (FTC) announced on Nov. 26, 2014 that it placed conditions upon the GlaxoSmithKline (GSK) and Novartis AG joint venture announced in April. FTC has required that Novartis AG divest Habitrol, its nicotine replacement therapy patch, and private-label patch business.
Under the agreement, GSK will be the majority shareholder with an equity interest of 63.5% in the new consumer healthcare company. However, the joint venture must meet the FTC requirements to preserve competition in the market for nicotine patches. GSK currently has its own nicotine replacement patch, Nicoderm CQ, a direct competitor of Habitrol.
“Potential competitors would find it difficult, expensive, and time-consuming to develop new patch products and secure FDA approval, reinforcing the substantial competitive concerns,” FTC wrote in a press release.
Source: FTC
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
